more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Biotech Initiates Phase III Trial for Heart Disease Drug

  ()
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock.
Tags: Biotechnology / Pharmaceuticals

Analyst Says Biotech's Data Supports Advancement Into Phase III

Research Report
  ()
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note.
Tags: Biotechnology / Pharmaceuticals

Rising Revenue and Strategic Pipeline Advances Propel Biotech Growth Trajectory

  ()
Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. Read the details on this announcement and some of the primary drivers behind the rise.
Tags: Biotechnology / Pharmaceuticals

Pharma Stock Has Significant Upside Potential, Analyst Says

Research Report
  ()
"We believe significant upside potential exists," H.C. Wainwright & Co. analysts wrote about Lexicon Pharmaceuticals Inc. (LXRX:NASDAQ) in an updated research note.
Tags: Biotechnology / Pharmaceuticals

Biotech Shares Positive Phase I Data for Alzheimer's Treatment

Research Report
  ()
Leede Financial Inc.'s target price on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) reflects a potential return of 822%.
Tags: Biotechnology / Pharmaceuticals

Mass. Biotech Shares Strong Q3 Results

Research Report
  ()
Kiniksa Pharmaceuticals Ltd. (KNSA:NASDAQ) recently reported strong Q3 2024 earnings, which led to its Outperform rating, according to a Wedbush research note.
Tags: Biotechnology / Pharmaceuticals

Boston Biotech Announces Novartis Collaboration

Research Report
  ()
Monte Rosa Therapeutics Inc. (GLUE:NASDAQ) recently unveiled a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program, according to a Wedbush research note.
Tags: Biotechnology / Pharmaceuticals

H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates

Research Report
  ()
DBV Technologies SA (DBVT:NASDAQ) received a raised target price after it released long-awaited regulatory clarity regarding the path forward for its Viaskin Peanut patch.
Tags: Biotechnology / Pharmaceuticals

Silver Break Out Confirmed

Contributed Opinion
  ()
The silver break out is confirmed, and Ron Struthers of Struthers Resource Stock Report expects a move to $50. He explains why he believes Coeur Mining Inc. (CDE:NYSE) offers good value and shares one biotech stock he believes is currently a sell.
Tags: SilverBiotechnology / PharmaceuticalsGold

NY Biopharma Shares Promising Clinical Data

Research Report
  ()
Anavex Life Sciences Corp. (AVXL:NASDAQ) recently released encouraging preliminary electroencephalography (EEG) biomarker results from Part A of the ongoing Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment, according to an H.C. Wainright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

H.C. Wainwright & Co. Shares Buy Rating on Biotech Co.

Research Report
  ()
H.C. Wainwright & Co. analysts gave Unicycive Therapeutics Inc. (UNCY:NASDAQ) a Buy rating after the company announced the successful completion of the Phase 1 study for UNI-494 in healthy volunteers.
Tags: Biotechnology / Pharmaceuticals

Mass. Biotech Receives FDA Approval

Research Report
  ()
Biofrontera Inc. (BFRI:NASDAQ) receieved FDA's approval of the company's supplemental Biologics License Application (sBLA) to expand the use of Ameluz for treating larger surface areas of actinic keratosis (AK) on the face and scalp, according to a Roth MKM research note.
Tags: Biotechnology / Pharmaceuticals

CT Biotech Ready for Clinical Milestones

Research Report
  ()
Trevi Therapeutics Inc. (TRVI:NASDAQ) has made progress in its clinical trials for Haduvio, particularly in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients and refractory chronic cough (RCC), according to an EF Hutton research note.
Tags: Biotechnology / Pharmaceuticals

Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial

Research Report
  ()
Following OS Therapies Inc.'s (OSTX:NYSEAMERICAN) announcement that the last patient enrolled in their Phase 2b trial for OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation, the company received a Buy rating and high target price from EF Hutton.
Tags: Biotechnology / Pharmaceuticals

New Jersey Biotech Reports Positive Survival Data

Research Report
  ()
H.C. Wainwright & Co. analysts Dr. Joseph Pantginis gave PDS Biotechnology Corp. (PDSB:NASDAQ) a Buy rating and large target price.
Tags: Biotechnology / Pharmaceuticals

California Biotech's Target Price 200% Higher Than Current

Research Report
  ()
F Hutton analyst Jason Kolbert gave Anixa Biosciences Inc. (ANIX: NASDAQ) a high target price after it had announced it would be amending the protocol for its ongoing CAR-T therapy clinical trial for ovarian cancer, allowing for a second dose in certain patients.
Tags: Biotechnology / Pharmaceuticals

Target Price Raised on Biotech Co.

Research Report
  ()
In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company.
Tags: Biotechnology / Pharmaceuticals

CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment

Research Report
  ()
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) recently reported positive Phase 3 data for its Schizophrenia treatment. The company also noted it intends to file an NDA in the first quarter of 2026, according to an EF Hutton Research note.
Tags: Biotechnology / Pharmaceuticals

Revolutionizing Chronic Disease Treatment Through Regenerative Medicine

  ()
A regenerative medicine therapeutics company focused on developing technologies to address chronic diseases through a regenerative approach, Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) is focused on reforming healthcare through technology. See why experts and analysts are praising this company's potential.
Tags: Medical DevicesBiotechnology / Pharmaceuticals

Is It Now Time To Buy This Biotech Stock?

Contributed Opinion
  ()
Technical Analyst Clive Maund shares his thoughts on Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) to explain why he believes it is a good stock to accumulate, between the current price and recent lows.
Tags: Biotechnology / PharmaceuticalsMedical Devices

California Biotech Reports Positive QOL Improvements in Program

Research Report
  ()
With Ontrak Inc.'s (OTRK:NASDAQ) significant results from the first six months of data collected through its implementation of ReQoL, Roth MKM analyst Dr, Jonathan Schoff gave the company a Buy rating.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment

  ()
Clinical stage biotechnology company Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) has released new data that show success in using its Cell Pouch Transplant System to help Type 1 diabetes patients reach insulin independence. One author says the company is David taking on Goliath in the race for a cure.
Tags: Biotechnology / PharmaceuticalsMedical Devices

Biotech Working on 'Functional Cure' for Type 1 Diabetes

  ()
Clinical-stage biotechnology company Sernova Corp.'s (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) Cell Pouch implantable technology can act as a "pseudo-organ," delivering therapeutic cells to the body. Find out why one newsletter author thinks the stock could deliver a big payoff for shareholders and for patients.
Tags: Biotechnology / Pharmaceuticals

MA Biotech Reports Positive Meeting with FDA

Research Report
  ()
Replimune Group Inc.'s (REPL:NASDAQ) announced a successful pre-Biologics License Application (BLA) meeting with the FDA, according to a Roth MKM research note.
Tags: Biotechnology / Pharmaceuticals

Mass. Biopharma Reports Positive Data and Announces New Program

Research Report
  ()
Wedbush analysts noted that they would be buyers ahead of Vor Biopharma Inc.'s (VOR:NASDAQ) planned regulatory updates and likely further data readouts.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 41 Next